A recent RCT published in the Journal of Functional Foods, reported Akay’s Fenumat formulation, characterisation and pharmacokinetic properties of two poorly bioavailable lipophilic phytonutrients, namely curcuminoids, and 3-Acetyl-11-keto-β-boswellic acid (AKBA), following their co-delivery at a single dose of 250 mg. Curcuminoids and boswellic acids are known to act synergistically for joint health and musculoskeletal pain. But the poor oral bioavailability contributed by the lipophilicity, water insolubility and rapid biotransformation and elimination have always posed inherent problems, Akay says.
The technology has already used in the delivery of free curcuminoids as curcumagalactomannosides (CGM or CurQfen) and has been shown to possess improved blood-brain-barrier permeability.